Brokerages Set Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) PT at $46.67

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) has earned an average rating of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $46.6667.

Several brokerages have issued reports on NBTX. Guggenheim initiated coverage on shares of Nanobiotix in a research note on Tuesday, September 15th. They issued a “buy” rating and a $64.00 price objective on the stock. Leerink Partners raised their target price on shares of Nanobiotix from $37.00 to $46.00 and gave the stock an “outperform” rating in a research note on Thursday, June 4th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Friday, July 17th.

Nanobiotix Stock Performance

Nanobiotix stock opened at $35.24 on Monday. The business has a 50 day simple moving average of $38.90 and a 200-day simple moving average of $37.40. Nanobiotix has a 12 month low of $14.30 and a 12 month high of $57.14.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. The company’s technology is designed to improve the effectiveness of radiotherapy by using nanoparticles that interact with radiation inside tumors, with the goal of enhancing tumor-cell destruction while limiting damage to surrounding healthy tissue.

Its lead product candidate, NBTXR3, is an investigational radioenhancer consisting of functionalized hafnium oxide nanoparticles.